FDA panel supports Novartis version of Amgen arthritis drug

July 13, 2016 7:28 PM

25 0

FDA panel supports Novartis version of Amgen arthritis drug

Novartis AG's cheaper version of Amgen Inc's arthritis drug Enbrel is highly similar in potency and safety to the original and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.

The panel voted 20-O that there is no clinically meaningful difference between Novartis's drug, a biologic made of living cells, and Enbrel. Copies of biologics are called biosimilars, not generics, because they are more difficult to imitate with precision.

Also read: Hong Kong leader won't seek new term

Read more

To category page

Loading...